Pasireotide 0.9 MG/ML

DRUG2 trials

Sponsors

Helsinki University Central Hospital, Gustave Roussy, Cancer Campus, Grand Paris

Conditions

Peritoneal CarcinomatosisSurgical Complications

Phase 2

Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis

TerminatedNCT04826432

Gustave Roussy, Cancer Campus, Grand ParisPeritoneal Carcinomatosis

Start: 2020-09-03End: 2024-02-07Updated: 2024-02-08

Unknown Phase

Impact of Pasireotide on Postoperative Pancreatic Fistulas Following Distal Resections

CompletedNCT04281680

Helsinki University Central HospitalSurgical Complications

Start: 2014-07-01End: 2016-04-30Updated: 2020-02-24